Protein Drugs-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data
Report Summary
Protein Drugs-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Protein Drugs industry, standing on the readers’ perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Protein Drugs 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Protein Drugs worldwide and market share by regions, with company and product introduction, position in the Protein Drugs market
Market status and development trend of Protein Drugs by types and applications
Cost and profit status of Protein Drugs, and marketing status
Market growth drivers and challenges
The report segments the global Protein Drugs market as:
Global Protein Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Protein Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Antibody Drugs
Peptide Hormones
Blood Products
Enzymes
Global Protein Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
AIDS
Cancer
Hepatitis
Diabetes
Others
Global Protein Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Protein Drugs Sales Volume, Revenue, Price and Gross Margin):
Eli Lilly
Abbott Laboratories
UCB Group
Schering-Plough Corporation
Genentech
Johnson&Johnson
Bristol-Myers Squibb
Novo Nordisk
Biogen Idec
Dendreon Corporation
Amgen
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Protein Drugs-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Protein Drugs industry, standing on the readers’ perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Protein Drugs 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Protein Drugs worldwide and market share by regions, with company and product introduction, position in the Protein Drugs market
Market status and development trend of Protein Drugs by types and applications
Cost and profit status of Protein Drugs, and marketing status
Market growth drivers and challenges
The report segments the global Protein Drugs market as:
Global Protein Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Protein Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Antibody Drugs
Peptide Hormones
Blood Products
Enzymes
Global Protein Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
AIDS
Cancer
Hepatitis
Diabetes
Others
Global Protein Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Protein Drugs Sales Volume, Revenue, Price and Gross Margin):
Eli Lilly
Abbott Laboratories
UCB Group
Schering-Plough Corporation
Genentech
Johnson&Johnson
Bristol-Myers Squibb
Novo Nordisk
Biogen Idec
Dendreon Corporation
Amgen
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF PROTEIN DRUGS
1.1 Definition of Protein Drugs in This Report
1.2 Commercial Types of Protein Drugs
1.2.1 Antibody Drugs
1.2.2 Peptide Hormones
1.2.3 Blood Products
1.2.4 Enzymes
1.3 Downstream Application of Protein Drugs
1.3.1 AIDS
1.3.2 Cancer
1.3.3 Hepatitis
1.3.4 Diabetes
1.3.5 Others
1.4 Development History of Protein Drugs
1.5 Market Status and Trend of Protein Drugs 2013-2023
1.5.1 Global Protein Drugs Market Status and Trend 2013-2023
1.5.2 Regional Protein Drugs Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Protein Drugs 2013-2017
2.2 Sales Market of Protein Drugs by Regions
2.2.1 Sales Volume of Protein Drugs by Regions
2.2.2 Sales Value of Protein Drugs by Regions
2.3 Production Market of Protein Drugs by Regions
2.4 Global Market Forecast of Protein Drugs 2018-2023
2.4.1 Global Market Forecast of Protein Drugs 2018-2023
2.4.2 Market Forecast of Protein Drugs by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Protein Drugs by Types
3.2 Sales Value of Protein Drugs by Types
3.3 Market Forecast of Protein Drugs by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Protein Drugs by Downstream Industry
4.2 Global Market Forecast of Protein Drugs by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Protein Drugs Market Status by Countries
5.1.1 North America Protein Drugs Sales by Countries (2013-2017)
5.1.2 North America Protein Drugs Revenue by Countries (2013-2017)
5.1.3 United States Protein Drugs Market Status (2013-2017)
5.1.4 Canada Protein Drugs Market Status (2013-2017)
5.1.5 Mexico Protein Drugs Market Status (2013-2017)
5.2 North America Protein Drugs Market Status by Manufacturers
5.3 North America Protein Drugs Market Status by Type (2013-2017)
5.3.1 North America Protein Drugs Sales by Type (2013-2017)
5.3.2 North America Protein Drugs Revenue by Type (2013-2017)
5.4 North America Protein Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Protein Drugs Market Status by Countries
6.1.1 Europe Protein Drugs Sales by Countries (2013-2017)
6.1.2 Europe Protein Drugs Revenue by Countries (2013-2017)
6.1.3 Germany Protein Drugs Market Status (2013-2017)
6.1.4 UK Protein Drugs Market Status (2013-2017)
6.1.5 France Protein Drugs Market Status (2013-2017)
6.1.6 Italy Protein Drugs Market Status (2013-2017)
6.1.7 Russia Protein Drugs Market Status (2013-2017)
6.1.8 Spain Protein Drugs Market Status (2013-2017)
6.1.9 Benelux Protein Drugs Market Status (2013-2017)
6.2 Europe Protein Drugs Market Status by Manufacturers
6.3 Europe Protein Drugs Market Status by Type (2013-2017)
6.3.1 Europe Protein Drugs Sales by Type (2013-2017)
6.3.2 Europe Protein Drugs Revenue by Type (2013-2017)
6.4 Europe Protein Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Protein Drugs Market Status by Countries
7.1.1 Asia Pacific Protein Drugs Sales by Countries (2013-2017)
7.1.2 Asia Pacific Protein Drugs Revenue by Countries (2013-2017)
7.1.3 China Protein Drugs Market Status (2013-2017)
7.1.4 Japan Protein Drugs Market Status (2013-2017)
7.1.5 India Protein Drugs Market Status (2013-2017)
7.1.6 Southeast Asia Protein Drugs Market Status (2013-2017)
7.1.7 Australia Protein Drugs Market Status (2013-2017)
7.2 Asia Pacific Protein Drugs Market Status by Manufacturers
7.3 Asia Pacific Protein Drugs Market Status by Type (2013-2017)
7.3.1 Asia Pacific Protein Drugs Sales by Type (2013-2017)
7.3.2 Asia Pacific Protein Drugs Revenue by Type (2013-2017)
7.4 Asia Pacific Protein Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Protein Drugs Market Status by Countries
8.1.1 Latin America Protein Drugs Sales by Countries (2013-2017)
8.1.2 Latin America Protein Drugs Revenue by Countries (2013-2017)
8.1.3 Brazil Protein Drugs Market Status (2013-2017)
8.1.4 Argentina Protein Drugs Market Status (2013-2017)
8.1.5 Colombia Protein Drugs Market Status (2013-2017)
8.2 Latin America Protein Drugs Market Status by Manufacturers
8.3 Latin America Protein Drugs Market Status by Type (2013-2017)
8.3.1 Latin America Protein Drugs Sales by Type (2013-2017)
8.3.2 Latin America Protein Drugs Revenue by Type (2013-2017)
8.4 Latin America Protein Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Protein Drugs Market Status by Countries
9.1.1 Middle East and Africa Protein Drugs Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Protein Drugs Revenue by Countries (2013-2017)
9.1.3 Middle East Protein Drugs Market Status (2013-2017)
9.1.4 Africa Protein Drugs Market Status (2013-2017)
9.2 Middle East and Africa Protein Drugs Market Status by Manufacturers
9.3 Middle East and Africa Protein Drugs Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Protein Drugs Sales by Type (2013-2017)
9.3.2 Middle East and Africa Protein Drugs Revenue by Type (2013-2017)
9.4 Middle East and Africa Protein Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF PROTEIN DRUGS
10.1 Global Economy Situation and Trend Overview
10.2 Protein Drugs Downstream Industry Situation and Trend Overview
CHAPTER 11 PROTEIN DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Protein Drugs by Major Manufacturers
11.2 Production Value of Protein Drugs by Major Manufacturers
11.3 Basic Information of Protein Drugs by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Protein Drugs Major Manufacturer
11.3.2 Employees and Revenue Level of Protein Drugs Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 PROTEIN DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Eli Lilly
12.1.1 Company profile
12.1.2 Representative Protein Drugs Product
12.1.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly
12.2 Abbott Laboratories
12.2.1 Company profile
12.2.2 Representative Protein Drugs Product
12.2.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories
12.3 UCB Group
12.3.1 Company profile
12.3.2 Representative Protein Drugs Product
12.3.3 Protein Drugs Sales, Revenue, Price and Gross Margin of UCB Group
12.4 Schering-Plough Corporation
12.4.1 Company profile
12.4.2 Representative Protein Drugs Product
12.4.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Schering-Plough Corporation
12.5 Genentech
12.5.1 Company profile
12.5.2 Representative Protein Drugs Product
12.5.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Genentech
12.6 Johnson&Johnson
12.6.1 Company profile
12.6.2 Representative Protein Drugs Product
12.6.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Johnson&Johnson
12.7 Bristol-Myers Squibb
12.7.1 Company profile
12.7.2 Representative Protein Drugs Product
12.7.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
12.8 Novo Nordisk
12.8.1 Company profile
12.8.2 Representative Protein Drugs Product
12.8.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Novo Nordisk
12.9 Biogen Idec
12.9.1 Company profile
12.9.2 Representative Protein Drugs Product
12.9.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Biogen Idec
12.10 Dendreon Corporation
12.10.1 Company profile
12.10.2 Representative Protein Drugs Product
12.10.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Dendreon Corporation
12.11 Amgen
12.11.1 Company profile
12.11.2 Representative Protein Drugs Product
12.11.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Amgen
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PROTEIN DRUGS
13.1 Industry Chain of Protein Drugs
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF PROTEIN DRUGS
14.1 Cost Structure Analysis of Protein Drugs
14.2 Raw Materials Cost Analysis of Protein Drugs
14.3 Labor Cost Analysis of Protein Drugs
14.4 Manufacturing Expenses Analysis of Protein Drugs
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
1.1 Definition of Protein Drugs in This Report
1.2 Commercial Types of Protein Drugs
1.2.1 Antibody Drugs
1.2.2 Peptide Hormones
1.2.3 Blood Products
1.2.4 Enzymes
1.3 Downstream Application of Protein Drugs
1.3.1 AIDS
1.3.2 Cancer
1.3.3 Hepatitis
1.3.4 Diabetes
1.3.5 Others
1.4 Development History of Protein Drugs
1.5 Market Status and Trend of Protein Drugs 2013-2023
1.5.1 Global Protein Drugs Market Status and Trend 2013-2023
1.5.2 Regional Protein Drugs Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Protein Drugs 2013-2017
2.2 Sales Market of Protein Drugs by Regions
2.2.1 Sales Volume of Protein Drugs by Regions
2.2.2 Sales Value of Protein Drugs by Regions
2.3 Production Market of Protein Drugs by Regions
2.4 Global Market Forecast of Protein Drugs 2018-2023
2.4.1 Global Market Forecast of Protein Drugs 2018-2023
2.4.2 Market Forecast of Protein Drugs by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Protein Drugs by Types
3.2 Sales Value of Protein Drugs by Types
3.3 Market Forecast of Protein Drugs by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Protein Drugs by Downstream Industry
4.2 Global Market Forecast of Protein Drugs by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Protein Drugs Market Status by Countries
5.1.1 North America Protein Drugs Sales by Countries (2013-2017)
5.1.2 North America Protein Drugs Revenue by Countries (2013-2017)
5.1.3 United States Protein Drugs Market Status (2013-2017)
5.1.4 Canada Protein Drugs Market Status (2013-2017)
5.1.5 Mexico Protein Drugs Market Status (2013-2017)
5.2 North America Protein Drugs Market Status by Manufacturers
5.3 North America Protein Drugs Market Status by Type (2013-2017)
5.3.1 North America Protein Drugs Sales by Type (2013-2017)
5.3.2 North America Protein Drugs Revenue by Type (2013-2017)
5.4 North America Protein Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Protein Drugs Market Status by Countries
6.1.1 Europe Protein Drugs Sales by Countries (2013-2017)
6.1.2 Europe Protein Drugs Revenue by Countries (2013-2017)
6.1.3 Germany Protein Drugs Market Status (2013-2017)
6.1.4 UK Protein Drugs Market Status (2013-2017)
6.1.5 France Protein Drugs Market Status (2013-2017)
6.1.6 Italy Protein Drugs Market Status (2013-2017)
6.1.7 Russia Protein Drugs Market Status (2013-2017)
6.1.8 Spain Protein Drugs Market Status (2013-2017)
6.1.9 Benelux Protein Drugs Market Status (2013-2017)
6.2 Europe Protein Drugs Market Status by Manufacturers
6.3 Europe Protein Drugs Market Status by Type (2013-2017)
6.3.1 Europe Protein Drugs Sales by Type (2013-2017)
6.3.2 Europe Protein Drugs Revenue by Type (2013-2017)
6.4 Europe Protein Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Protein Drugs Market Status by Countries
7.1.1 Asia Pacific Protein Drugs Sales by Countries (2013-2017)
7.1.2 Asia Pacific Protein Drugs Revenue by Countries (2013-2017)
7.1.3 China Protein Drugs Market Status (2013-2017)
7.1.4 Japan Protein Drugs Market Status (2013-2017)
7.1.5 India Protein Drugs Market Status (2013-2017)
7.1.6 Southeast Asia Protein Drugs Market Status (2013-2017)
7.1.7 Australia Protein Drugs Market Status (2013-2017)
7.2 Asia Pacific Protein Drugs Market Status by Manufacturers
7.3 Asia Pacific Protein Drugs Market Status by Type (2013-2017)
7.3.1 Asia Pacific Protein Drugs Sales by Type (2013-2017)
7.3.2 Asia Pacific Protein Drugs Revenue by Type (2013-2017)
7.4 Asia Pacific Protein Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Protein Drugs Market Status by Countries
8.1.1 Latin America Protein Drugs Sales by Countries (2013-2017)
8.1.2 Latin America Protein Drugs Revenue by Countries (2013-2017)
8.1.3 Brazil Protein Drugs Market Status (2013-2017)
8.1.4 Argentina Protein Drugs Market Status (2013-2017)
8.1.5 Colombia Protein Drugs Market Status (2013-2017)
8.2 Latin America Protein Drugs Market Status by Manufacturers
8.3 Latin America Protein Drugs Market Status by Type (2013-2017)
8.3.1 Latin America Protein Drugs Sales by Type (2013-2017)
8.3.2 Latin America Protein Drugs Revenue by Type (2013-2017)
8.4 Latin America Protein Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Protein Drugs Market Status by Countries
9.1.1 Middle East and Africa Protein Drugs Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Protein Drugs Revenue by Countries (2013-2017)
9.1.3 Middle East Protein Drugs Market Status (2013-2017)
9.1.4 Africa Protein Drugs Market Status (2013-2017)
9.2 Middle East and Africa Protein Drugs Market Status by Manufacturers
9.3 Middle East and Africa Protein Drugs Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Protein Drugs Sales by Type (2013-2017)
9.3.2 Middle East and Africa Protein Drugs Revenue by Type (2013-2017)
9.4 Middle East and Africa Protein Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF PROTEIN DRUGS
10.1 Global Economy Situation and Trend Overview
10.2 Protein Drugs Downstream Industry Situation and Trend Overview
CHAPTER 11 PROTEIN DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Protein Drugs by Major Manufacturers
11.2 Production Value of Protein Drugs by Major Manufacturers
11.3 Basic Information of Protein Drugs by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Protein Drugs Major Manufacturer
11.3.2 Employees and Revenue Level of Protein Drugs Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 PROTEIN DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Eli Lilly
12.1.1 Company profile
12.1.2 Representative Protein Drugs Product
12.1.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly
12.2 Abbott Laboratories
12.2.1 Company profile
12.2.2 Representative Protein Drugs Product
12.2.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories
12.3 UCB Group
12.3.1 Company profile
12.3.2 Representative Protein Drugs Product
12.3.3 Protein Drugs Sales, Revenue, Price and Gross Margin of UCB Group
12.4 Schering-Plough Corporation
12.4.1 Company profile
12.4.2 Representative Protein Drugs Product
12.4.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Schering-Plough Corporation
12.5 Genentech
12.5.1 Company profile
12.5.2 Representative Protein Drugs Product
12.5.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Genentech
12.6 Johnson&Johnson
12.6.1 Company profile
12.6.2 Representative Protein Drugs Product
12.6.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Johnson&Johnson
12.7 Bristol-Myers Squibb
12.7.1 Company profile
12.7.2 Representative Protein Drugs Product
12.7.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
12.8 Novo Nordisk
12.8.1 Company profile
12.8.2 Representative Protein Drugs Product
12.8.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Novo Nordisk
12.9 Biogen Idec
12.9.1 Company profile
12.9.2 Representative Protein Drugs Product
12.9.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Biogen Idec
12.10 Dendreon Corporation
12.10.1 Company profile
12.10.2 Representative Protein Drugs Product
12.10.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Dendreon Corporation
12.11 Amgen
12.11.1 Company profile
12.11.2 Representative Protein Drugs Product
12.11.3 Protein Drugs Sales, Revenue, Price and Gross Margin of Amgen
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PROTEIN DRUGS
13.1 Industry Chain of Protein Drugs
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF PROTEIN DRUGS
14.1 Cost Structure Analysis of Protein Drugs
14.2 Raw Materials Cost Analysis of Protein Drugs
14.3 Labor Cost Analysis of Protein Drugs
14.4 Manufacturing Expenses Analysis of Protein Drugs
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference